Interleukin Genetics Inc (ILIU)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
*** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know

135 BEAVER ST WATHAM, MA 02452

Interleukin Genetics is a health company that develops genetic tests. Co. uses functional genomics to help in the development of risk assessment tests based on the genetic variations in people. Co. has commercialized genetic tests for periodontal disease risk assessment, cardiovascular risk assessment, general nutrition assessment, weight management and bone health. Co. sold its nutritional product brands, including Ginsana, Ginkoba, and Venastat, through the nation's largest food, drug and mass retailers. Co.'s development programs focus on commercializing its weight management and periodontal genetic risk assessment tests.

View SEC Filings from ILIU instead.
Q4 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
No data found for this quarter.
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ILIU (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ILIU BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

TOUTAIN STEPHAN CHIEF COMMERCIAL OFFICER

  • Officer
0 2017-04-19 0

KORNMAN KENNETH S PRESIDENT AND CSO

  • Officer
  • Director
0 2017-01-25 0

MILLS WILLIAM C. III

  • Director
0 2017-01-25 0

CARBEAU MARK B CEO

  • Officer
  • Director
0 2017-01-25 0

WEAVER JAMES M

  • Director
0 2017-01-25 0

PYXIS INNOVATIONS INC

ALTICOR GLOBAL HOLDINGS INC.

SOLSTICE HOLDINGS INC

ALTICOR INC

  • 10% Owner
42,595,659 2016-07-29 0

BAY CITY CAPITAL LLC

BAY CITY CAPITAL FUND V, L.P.

BAY CITY CAPITAL FUND V CO-INVESTMENT FUND, L.P.

BAY CITY CAPITAL MANAGEMENT V LLC

  • 10% Owner
77,245,201 2016-07-29 0

GROWTH EQUITY OPPORTUNITIES FUND III, LLC

NEA PARTNERS 14, L.P.

NEA 14 GP, LTD

NEW ENTERPRISE ASSOCIATES 14, L.P.

  • 10% Owner
55,418,811 2016-07-29 0

WELLER HARRY R

  • 10% Owner
55,418,811 2016-07-29 0

VISWANATHAN RAVI

  • 10% Owner
55,418,811 2016-07-29 0

SONSINI PETER W.

  • 10% Owner
55,418,811 2016-07-29 0

SANDELL SCOTT D

  • 10% Owner
55,418,811 2016-07-29 0

MOTT DAVID M

  • 10% Owner
55,418,811 2016-07-29 0

KOLLURI KRISHNA KITTU

  • 10% Owner
55,418,811 2016-07-29 0

KERINS PATRICK J

  • 10% Owner
55,418,811 2016-07-29 0

FLORENCE ANTHONY A. JR.

  • 10% Owner
55,418,811 2016-07-29 0

BASKETT FOREST

  • 10% Owner
55,418,811 2016-07-29 0

BARRIS PETER J

  • 10% Owner
55,418,811 2016-07-29 0

BARRETT M JAMES

  • 10% Owner
55,418,811 2016-07-29 0

DIPALMA STEPHEN J. INTERIM CFO

  • Officer
349,855 2016-07-29 0

SNYDER SCOTT A. CHIEF MARKETING OFFICER

  • Officer
0 2015-01-22 0

DRANT RYAN D

  • 10% Owner
35,298,087 2014-12-23 0

LURIER ELIOT M CHIEF FINANCIAL OFFICER

  • Officer
0 2011-03-23 0

BENDER LEWIS H CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
0 2011-02-14 0

EHRENBERGER CATHERINE

  • Director
0 2010-07-30 0

CHOWNING MARY E

  • Director
30,000 2010-03-17 0

ARMSTRONG GLENN S

  • Director
0 2008-07-24 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments